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ABSTRACT
By combining electrophysiological and computational ap-
proaches we have examined a series of positive allosteric
modulators (PAMs) acting on the human a7 nicotinic acetyl-
choline receptor (nAChR). Electrophysiological studies have
focused on three a7-selective PAMs (A-867744, TBS-516, and
TQS) that display similar effects on wild-type a7 nAChRs. In
addition to potentiating agonist-evoked responses, all three
compounds reduce receptor desensitization and, conse-
quently, are classed as type II PAMs. Despite having similar
effects on wild-type receptors, A-867744 was found to have
profoundly differing effects on mutated receptors compared
with TBS-516 and TQS, a finding that is consistent with
previous studies indicating that A-867744 may have a different
mechanism of action compare with other a7-selective type II
PAMs. Due to evidence that these PAMs bind within the a7
nAChR transmembrane region, we generated and validated
new structural models of a7. Importantly, we have corrected a
previously identified error in the transmembrane region of the
original cryo–electron microscopy Torpedo model; the only
pentameric ligand-gated ion channel imaged in a native lipid
membrane. Real-space refinement was used to generate
closed and open conformations on which the a7 models were
based. Consensus docking with an extended series of PAMs
with chemical similarity to A-867744, TBS-516, and TQS
suggests that all bind to a broadly similar intersubunit trans-
membrane site. However, differences in the predicted binding
of A-867744, compared with TBS-516 and TQS, may help to
explain the distinct functional effects of A-867744. Thus, our
revised structural models may provide a useful tool for
interpreting functional effects of PAMs.
Introduction
Nicotinic acetylcholine receptors (nAChRs) are members of
a family of pentameric ligand-gated ion channels (pLGICs)
that also includes receptors for 5-hydroxytrptamine, g-amino-
butyric acid and glycine (Lester et al., 2004). There has been
considerable interest in the identification of positive allosteric
modulators (PAMs) of nAChRs (Bertrand and Gopalak-
rishnan, 2007; Williams et al., 2011; Chatzidaki and Millar,
2015). In particular, extensive efforts have been aimed at the
generation of PAMs that are selective for homomeric a7
nAChRs (Faghih et al., 2008; Malysz et al., 2009b), a receptor
subtype that is implicated in a range of neurological and
psychiatric disorders (Haydar and Dunlop, 2010; Parri et al.,
2011; Hurst et al., 2013). The a7 nAChR undergoes rapid
desensitization when activated by the binding of conven-
tional agonists such as acetylcholine to the extracellular
orthosteric agonist-binding site (Couturier et al., 1990).
However, agonist activation of a7 nAChRs is sensitive to
modulation by a variety of allosteric ligands (Chatzidaki and
Millar, 2015). PAMs acting on a7 nAChRs are classified as
either type I or type II PAMs, reflecting their differing effects
upon agonist-induced desensitization. Whereas type I PAMs
have little or no effect on desensitization, type II PAMs cause
a reduction in receptor desensitization, as well as potentiat-
ing peak agonist responses (Bertrand and Gopalakrishnan,
2007).
Among the chemically diverse family of a7 nAChR PAMs, a
subset of compounds share the common feature of an arylsul-
fonamide group. In the present study, we have examined the
pharmacological properties of three arylsulfonamide PAMs
[4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)
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benzenesulfonamide (A-867744), 4-(5-benzyl-3-(4-bromophenyl)-
1H-1,2,4-triazol-1-yl)benzene sulfonamide (TBS-516), and
cis-cis-4-(napthalen-1-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]
quinoline-8-sulfonamide (TQS)] (Fig. 1) that are representative
of three distinct subfamilies of a7-selective type II PAMs.
A-867744 is a member of a family of PAMs that contains a
central pyrrole core (Faghih et al., 2009; Malysz et al., 2009a).
TBS-516 is representative of a group of PAMs containing a
central triazole core (Chatzidaki et al., 2015), whereas TQS is
one of a group of PAMs that contain a cyclopenta[c]quinoline core
(Grønlien et al., 2007; Gill et al., 2012; Gill-Thind et al., 2015). In
common with other a7-selective type II PAMs the three
compounds potentiate agonist-evoked responses and also reduce
desensitization (Grønlien et al., 2007; Malysz et al., 2009a; Gill
et al., 2011; Chatzidaki et al., 2015).
For all three families of arylsulfonamide PAMs examined in
this study, there is evidence derived from artificial subunit
chimeras that the compounds exert their functional effects by
binding at a transmembrane site (Malysz et al., 2009a; Gill
et al., 2011; Chatzidaki et al., 2015). In addition, competition
radioligand binding studies have shown that none of these
PAMs displace the binding of antagonists from the a7 nAChR
orthosteric binding site (Malysz et al., 2009a; Chatzidaki
et al., 2015; Gill-Thind et al., 2015). These findings are
consistent with the PAMs interacting with a transmembrane
allosteric site, as has been proposed for a broader group of a7
nAChR allostericmodulators (Young et al., 2008; Collins et al.,
2011; Gill-Thind et al., 2015). However, some unexpected
results have been reported for A-867744 that are not observed
with other a7-selective PAMs. Although A-867744 does not
displace the binding of the orthosteric antagonist [3H]-
methyllycaconitine (MLA), it has been reported to displace
the binding of an a7-selective agonist [(1S,4S)-2,2-dimethyl-5-
(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane
([3H]-A-585539)] that is believed to interact with the orthos-
teric site (Anderson et al., 2008). This is not necessarily
incompatible with A-867744 binding to a transmembrane
site, because there is evidence that PAMs interacting with a
transmembrane site can induce conformational changes in
the orthosteric ligand-binding domain (Barron et al., 2009).
Nevertheless, it suggests that A-867744 may cause confor-
mational changes in the receptor that are different from those
caused by other PAMs.
In summary, the pharmacological effects of A-867744 have
been compared with those of two chemically similar PAMs
(TBS-516 and TQS) on both wild-type and mutated a7
nAChRs. In addition, two revised comparative models of the
human a7 nAChRs have been generated based on the closed
and open structures of the Torpedo nAChR (Unwin and
Fujiyoshi, 2012). Importantly, the models were generated
after correcting an apparent error in the assignment of amino
acids in the transmembrane domain that has been identified
previously on the basis of comparisons with other pLGIC
structures and biochemical studies (Corringer et al., 2010;
Hibbs and Gouaux, 2011; Mnatsakanyan and Jansen, 2013).
Molecular docking studies with the revised a7 structural
models help to explain the pharmacological diversity observed
among a group of type II PAMs with close chemically
similarity.
Materials and Methods
Chemical Synthesis. TBS-516 and TQS were synthesized as
described previously (Gill et al., 2012; Chatzidaki et al., 2015).
A-867744 was purchased from Tocris Bioscience (Bristol, UK).
Site-Directed Mutagenesis and Complementary RNA Syn-
thesis. Site-directed mutagenesis was performed on human nAChR
a7 subunit cDNA in plasmid pSP64GL (Broadbent et al., 2006) using
the QuikChange Mutagenesis Kit (Stratagene, La Jolla, CA) and was
verified by nucleotide sequencing. Plasmid pSP64GL containing wild-
type or mutated human a7 cDNA was linearized with BamHI and
purified with QIAQuik PCR Purification Kit (Qiagen, Crawley, UK).
In vitro synthesis of complementary RNA was performed using an
mMessage mMachine SP6 Transcription Kit (Invitrogen Life Tech-
nologies, Carlsbad, CA). For consistency with previous studies, the
numbering of amino acids altered by site-directed mutagenesis is
based on the predicted signal sequence cleavage site in the chicken a7
protein, as reported previously (Couturier et al., 1990).
Xenopus Oocyte Electrophysiology. Heterologous expression
was achieved by injection of wild-type or mutated a7 complementary
RNA (6–12 ng) into the cytoplasm of defolliculated Xenopus laevis
oocytes, as described previously (Young et al., 2007). After injection,
oocytes were incubated at 18°C in a calcium-containing Barth’s
solution supplemented with antibiotics (100 U/ml penicillin, 100 mg/ml
streptomycin, 4 mg/ml kanamycin, and 50 mg/ml tetracycline). Experi-
ments were performed on oocytes after 3–5 days of incubation. Oocytes
were placed in a recording chamber and continuously perfused with a
saline solution with a flow rate of approximately 15 ml/min. Two-
electrode voltage-clamp recordings were performed as described pre-
viously (Young et al., 2007; Gill et al., 2012).
Radioligand Binding. Human kidney tsA201 cells were cultured
in Dulbecco’s modified Eagle’s medium (Invitrogen Life Technologies)
containing 10% fetal calf serum (Sigma-Aldrich, St. Louis, MO),
penicillin (100 U/ml), and streptomycin (100 mg/ml) (Invitrogen Life
Technologies). Cells were maintained in a humidified incubator
Fig. 1. Chemical structures of a7 nAChR PAMs
and nAChR mutations. (A) The structure of the
three compounds examined by electrophysiologi-
cal techniques are shown (A-867744, TBS-516,
and TQS). In addition, a larger group of PAMs
with close chemical similarity to these three
compounds (7 compounds similar to A-867744,
3 similar to TBS-516, and 24 similar to TQS) were
selected for computer docking studies. Details of
the chemical structure of all 37 compounds se-
lected for docking studies is provided in Supple-
mental Table 1. (B) Location of a7 nAChR amino
acids examined by site-directed mutagenesis. Mu-
tated amino acids are indicated as spheres and
correspond to W54 (coral), S222 (green), L247
(blue), M253 (yellow), and M260 (red).
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containing 5% CO2 at 37°C and transiently transfected with expres-
sion plasmids (pRK5-ha7 pRK5-hRIC-3) encoding human a7 nAChR
and human RIC-3 (Lansdell et al., 2005) using Effectene (Qiagen),
according to the manufacturer instructions. After overnight incuba-
tion in Effectene, cells were incubated at 37°C for 24–48 h before being
assayed for radioligand binding with [3H]-a-bungarotoxin ([3H]-
a-BTX) (56 Ci/mmol; Tocris Bioscience). Radioligand binding to
transiently transfected tsA201 cells was performed essentially as
described previously (Cooper and Millar, 1998; Lansdell and Millar,
2004). Transfected cells were resuspended in Hank’s balanced salt
solution (Gibco, Paisley, UK) containing 1% bovine serum albumin
and incubated with [3H]-a-BTX for 2 h at 22°C in a total volume of
150ml. Nonspecific bindingwas determined in the presence of nicotine
(1 mM) and carbamylcholine (1 mM). Competition binding experi-
ments were performed by incubating triplicate samples of transfected
cells with [3H]-a-BTX (1 nM), together with a range of concentrations
of either PAMs orMLA. Radioligand binding was assayed by filtration
onto Whatman GF/A filters (presoaked in 0.5% polyethylenimine),
followed by rapid washing with phosphate-buffered saline (Oxoid,
Basingstoke, UK) using a Brandel (Gaithersburg, MD) cell harvester.
Bound radioligand was quantified by scintillation counting.
Hierarchical Refinement of Torpedo nAChR. An apparent
error in the assignment of amino acids to the 4.0 Å electron cryo-
microscopy (cryo-EM) Torpedo nAChR density map within the second
and third transmembrane (TM) helices (TM2 and TM3) has been
identified previously (Corringer et al., 2010; Hibbs and Gouaux, 2011;
Mnatsakanyan and Jansen, 2013). Initially, the Torpedo ag subunit
was adjusted withMODELLER version 9.10 (Sali and Blundell, 1993)
using a sequence-structure alignment with a shift correction. One
hundred models of the Torpedo ag subunit were built, based on an
alignment to the 4Å atomicmodel [ProteinDataBank identifyer (PDB
ID) 2BG9] (Unwin, 2005) containing a four-residue gap added after the
previously assigned position of P236. The intracellular TM3-TM4
helix was removed because it wasmodeled poorly relative to the rest of
the model (due to lack of restraints in this region), and the sequences
were realigned at the start of TM4. The model with the highest
discrete optimized protein energy (Shen and Sali, 2006) scorewas then
refined via a hierarchical approach in the cryo-EMdensitymaps of the
Torpedo nAChR in both closed and open conformations at 6.2 Å
(Electron Microscopy Data Bank codes EMD-2071 and EMD-2072)
(Unwin and Fujiyoshi, 2012) (Supplemental Fig. 1). Initially, each of
the maps was segmented around the associated PDB atomic models
(PDB IDs 4AQ9 and 4AQ5) using the UCSF Chimera (Resource for
Biocomputing, Visualization, and Informatics, University of California,
San Francisco, San Francisco, CA) zone tool (Pettersen et al., 2004).
Densities corresponding to the neighboring subunits and the intracel-
lular TM3-TM4 helix were removed manually. In the first stage of
refinement, rigid bodies corresponding to secondary structure elements
were determined using the RIBFIND server (Pandurangan and Topf,
2012), and Flex-EM refinement was applied (Topf et al., 2008). In the
second stage, to improve the fit of the loop between TM1 and TM2, loop
modeling was carried out with MODELLER, generating 200 loops. The
loops were ranked by their segment-based cross-correlation coefficient
using TEMPy (Farabella et al., 2015), with the highest-ranking loop
(with a segment-based cross-correlation coefficient of 0.82) clearly
following the density shape. In the third stage, the model containing
the refined loopwas used as input for normalmode-based flexible fitting
with iMODFIT (Lopéz-Blanco and Chacon, 2013) into the density maps
of both closed and open conformations of the Torpedo nAChR (EMD-
2071 and EMD-2072, respectively) (Unwin and Fujiyoshi, 2012). In the
final stage, the open and closed models produced by iMODFIT were
energyminimizedusing all-atom conjugate gradient refinement inFlex-
EM. For the purpose of this study, we assessed the transmembrane
region of the final model using two methods. Agreement with the
density was tested using the segment-based Manders’ overlap co-
efficient (Joseph et al., 2016), and the quality of the model relative to
the initial model was assessed by the statistical potential metric
DQMEANBrane (Studer et al., 2014). PDB files are available for the
refined structural models of the Torpedo ag subunit in the closed and
open conformations (Supplemental Material).
Revised a7 Comparative Models. Comparative models of the
human a7 nAChR were generated. The top-ranked closed and open
refined models of the Torpedo ag subunit were used as the templates
on which we modeled the human a7 nAChR closed and open subunits
(Supplemental Fig. 2). One hundred models of a7 were generated for
each template using MODELLER version 9.10 (Sali and Blundell,
1993). The mean of QMEANBrane scores (calculated over all individ-
ual residues) were determined for each model and used as a ranking
criterion. The highest-scoringmodel was selected for each of the closed
and open conformations. The corresponding a7 subunit models were
then superposed on their corresponding templates, and 5-fold sym-
metry was imposed using the Chimera sym command (based on the
origin of the closed and open density maps). This created pentameric
models for each conformation of a7, which were examined using
MolProbity (Chen et al., 2010). Suggested side chain flips were applied
to reduce clashes, while keeping side chain rotamers as close to the
corrected torpedo model as possible. PDB files are available for the
human pentameric a7 nAChR structural model in the closed and open
conformations (Supplemental Material).
Small-Molecule Docking. To identify potential binding sites for
PAMs in the a7 nAChR closed and open comparative models, a
consensus small-molecule docking protocol was developed (Supple-
mental Fig. 3). Docking was performed with a series of 37 compounds
that have close chemical similarity to A-867744 (eight compounds),
TBS-516 (four compounds), or TQS (25 compounds), all of which are
known to display type II PAM or allosteric agonist/PAM activity on a7
nAChRs (for details of the selected compounds, see Supplemental
Table 1). Initially, rigid docking was performed with models of the
human a7 nAChR in both closed and open conformations, and the
results obtained with two different docking programs that have been
shown to produce reliable results (Wang et al., 2016) [GOLD; Cam-
bridge Crystallographic Data Centre, Cambridge, UK (Verdonk et al.,
2003) and AutoDock Vina; Molecular Graphics Lab at The Scripps
Research Institute, La Jolla, CA (Trott and Olson, 2010)] were
compared. With GOLD, the search area was defined such that all
receptor residues within a sphere of 18 Å radius from the g-carbon of
T277 of the (1) subunit in the closed model were included. With
AutoDock Vina, all receptor residues within a cube of 32 Å centered on
T277 of the (1) subunit were included. This search area spanned a
region covering both the intersubunit and intrasubunit cavities pre-
sent in the transmembrane domain. The search efficiency was set to
themaximum in both software packages, and the ligandswere allowed
full flexibility. Fifty diverse solutions were generated in GOLD, and
the maximum of 20 solutions was enabled in AutoDock Vina (via
20 runs). The root mean square deviation (RMSD) between the GOLD
and AutoDock Vina solutions for each ligandwas determined using an
in-house python script based on the Hungarian algorithm (Allen and
Rizzo, 2014). A centroid was defined based on the location of all atoms
in the solutions that had an RMSD of 2.0 Å or less between GOLD and
AutoDock Vina. From this centroid, a region was determined that
included the positions of all the solutions in the subset (a sphere in
GOLD and a box in AutoDock Vina). Ten amino acid side chains were
selected for full flexibility within the defined docking areas in both
cases. Priority was given to making residues flexible that had been
mutated in this study, followed by polar residues and, finally, an even
distribution of flexible residues with the aim of preventing any bias to
particular regions of the selected binding area. All ligands were
docked using the same search parameters that were used for docking
studies with the rigid receptor (see above). RMSD filteringwas carried
out as previously, to remove solutions that had an RMSD greater than
2.0 Å between any of the GOLD and AutoDock solutions. The
remaining solutions after redundancy removal (up to 20 pairs) were
ranked based on the Borda score (Farabella et al., 2015) using the
following three metrics: the AutoDock Vina scoring function, and two
scoring functions used in GOLD (GoldScore and ChemPLP; Cambridge
Crystallographic Data Centre). After the docking simulation of all
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ligands, the top five ranked solutions from each chemical class were
clustered against each other (based on the GOLD pose) by hierarchical
RMSD clustering using an in-house script. The latter step was
performed to identify binding modes predicted consistently across
multiple compounds with a similar chemical structure. For each of the
three classes of arylsulfonamide type II PAMs, the most highly
populated clusters were assumed to represent the most probable
location of the binding site. PDB files are available for A-867744,
TBS-516, and TQS docked into the human a7 nAChR structural model
in the closed and open conformations (Supplemental Material)
Results
Radioligand Binding. As has been discussed previously
(Malysz et al., 2009a), an unexpected finding concerning the
a7-selective PAM A-867744 (Fig. 1) is that it causes the
dissociation of a radiolabeled agonist ([3H]-A-585539) that is
believed to bind to the a7 extracellular orthosteric binding
site. In the present study, we have examined the ability of
A-867744 to displace a radiolabeled antagonist ([3H]-a-BTX)
that is known to bind to the a7 orthosteric site. A-867744
caused no significant displacement of the binding of [3H]-
a-BTX to a7 nAChRs (Fig. 2). In contrast, and as expected, the
orthosteric antagonist MLA caused complete displacement of
[3H]-a-BTX (Fig. 2). These findings are consistent with pre-
vious studies demonstrating that A-867744 does not displace
[3H]-MLA from a7 nAChRs (Malysz et al., 2009a) and provide
additional support for the conclusion that A-867744 does not
bind to the orthosteric site.
Functional Characterization of a7-Selective PAMs.
Given the evidence that A-867744 has properties that are
different from those of other a7-selective type II PAMs
(Malysz et al., 2009a), the functional effects of A-867744,
TBS-516, and TQS were examined on a7 nAChRs containing
five different point mutations. The five mutations examined
have all been shown previously to influence allosteric modu-
lation of a7 nAChRs (Young et al., 2008; Papke et al., 2014).
Three of the mutations are located within TM2 (L247T,
M253L, and M260L), one mutation within TM1 (S222M),
and one mutation in the extracellular domain, at the orthos-
teric binding site (W54A). The effects of the five mutations on
A-867744, TBS-516, and TQS are summarized in Table 1 and
are also described in more detail below.
Allosteric Modulation of a7M260L. We have reported
previously that the M260L mutation, located within the a7
nAChRTM2 domain, is able to convert type II PAMs that have
little or no agonist effects on wild-type a7 nAChRs in allosteric
agonists (Chatzidaki et al., 2015). In agreement with these
previous findings, TBS-516 and TQS were found to activate
a7M260L with maximum responses that were higher than
acetylcholine (3.7 6 0.6-fold and 1.5 6 0.1-fold, respectively)
with EC50 values of 8.9 6 2.5 and 12.0 6 1.1 mM, respectively
(Fig. 3A). In marked contrast, A-867744 failed to evoke any
agonist responses on a7M260L (Fig. 3A), even at high concen-
trations (100 mM) but, instead, retained its PAM activity (Fig.
3B). Indeed, the potentiation of responses to acetylcholine
(100 mM) by A-867744 (1 mM) on a7M260L was not significantly
different from that on wild-type a7 (14.96 5.1-fold and 17.16
2.7-fold, respectively). In addition, preapplication of A-867744
completely blocked the agonist responses elicited by either
TBS-516 or TQS on a7M260L (Fig. 3, C and D).
Allosteric Modulation of a7L247T. Previous studies have
described the effects of the L247T mutation in the a7 nAChR
(a7L247T) (Revah et al., 1991). One of the most dramatic effects
of this mutation, which is located in the TM2 helix, is to
convert a variety of ligands that do not have agonist activity on
wild-type nAChRs into agonists. For example, this effect on
a7L247T has been reported for antagonists (Bertrand et al.,
1992; Palma et al., 1996), type I PAMs (Chatzidaki et al.,
2015), type II PAMs (Gill et al., 2011), and also for silent
allosteric modulators (Gill-Thind et al., 2015). In agreement
with these previous studies, we have found that both TBS-516
and TQS act as agonists on a7L247T with EC50 values of 0.4 6
0.1 and 0.2 6 0.04 mM, respectively (Fig. 4A). In contrast, no
agonist activity was observed on a7L247T with A-867744
(Fig. 4A). Whereas A-867744 acts as a PAM when coapplied
with acetylcholine on wild-type a7 nAChRs (Malysz et al.,
Fig. 2. Competition radioligand binding. Equilibrium radioligand binding
was performed with [3H]-a-BTX (1 nM) in human kidney tsA201 cells
expressing a7 nAChRs. A-867744 (3 nM to 30 mM) caused no significant
displacement of [3H]-a-BTX binding, whereas the orthosteric antagonist
MLA caused complete displacement of specific radioligand binding. Data
points aremeans of triplicate samples (6S.E.M.) from a single experiment,
and data are typical of three independent experiments.
TABLE 1
Pharmacological effects of three arylsulfonamide compounds (A-867744, TBS-516, and TQS) on wild-type
a7 nAChRs and on a7 nAChRs containing single-point mutations
Wild Type W54A S222M L247T M253L M260L
A-867744 PAM PAM Inhibitor/PAMa Inhibitor Inhibitor PAM
TBS-516 PAM Agonist PAM Agonist ,PAMb Agonist
TQS PAM Agonist PAM Agonist ,PAMb Agonist
aPositive modulatory effects (reduction in agonist-evoked desensitization) were associated with a reduction in peak
agonist-evoked responses.
bIndicates a substantial reduction or abolition of PAM activity.
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2009a), the coapplication of A-867744 (1 mM) on a7L247T
inhibited responses to a maximal concentration of acetylcho-
line (10 mM) (66% 6 1.2%) (Fig. 4B). In addition, the same
concentration of A-867744 completely blocked agonist re-
sponses to a maximal concentration of TBS-516 (10 mM) and
TQS (10 mM) (Fig. 4, C and D). It is noteworthy that the
application of A-867744 alone caused a decrease in the
baseline current on a7L247T (Fig. 4B). Previous studies have
reported that the L247T mutation causes an increase in the
frequency of spontaneous openings in a7 nAChRs (Bertrand
et al., 1997), so it is likely that A-867744 may be inhibiting
these spontaneous openings in a7L247T.
Allosteric Modulation of a7M253L. The influence of a
third mutation (M253L) within the TM2 domain of a7
(a7M253L) was examined. M253L has been reported previously
to reduce or abolish the potentiating effect of several allosteric
ligands (Young et al., 2008; Gill et al., 2011). In agreement
with these previous studies, coapplication of TQS (10mM)with
acetylcholine (100mM) on a7M253L did not result in an increase
in peak current (Fig. 5A). Furthermore, coapplication of
TBS-516 (10 mM) with acetylcholine (100 mM) on a7M253L
resulted in only a small increase in peak current (1.86 0.2-fold
potentiation; n 5 4) (Fig. 5B). In contrast, A-867744 (1 mM)
acted as an antagonist, producing a complete block of
responses to acetylcholine (100 mM) with an IC50 value of
70.2 6 13.5 nM (Fig. 5, C and E). The block by A-867744 was
surprisingly long lasting, as illustrated by responses to
acetylcholine failing to recover even after a long (10 minutes)
wash (Fig. 5C). Interestingly, when TQS was preapplied
before the application of A-867744, antagonism of acetylcho-
line responses by A-867744 was not observed (Fig. 5D).
However, after washing to remove TQS and A-867744, no
subsequent response to acetylcholine could be detected, even
after a prolonged wash (Fig. 5D). This may be because
A-867744 dissociates more slowly from the receptor than
TQS or perhaps that A-867744 is able to reassociate with
the receptor during the wash period.
Fig. 3. Allosteric modulation of a7M260L by A-867744, TBS-516, and TQS.
Mutated a7M260L nAChRs were expressed in Xenopus oocytes and
examined by two-electrode voltage-clamp recording. (A) Concentration-
response data illustrating agonist activation by TBS-516 and TQS but the
absence of agonist activity with A-867744. Data are the mean 6 S.E.M. of
three independent experiments, each from different oocytes. Data are
normalized to the maximum acetylcholine response. (B) Representative
traces illustrating responses to acetylcholine (100 mM; left) together with
acetylcholine responses fromthe sameoocyteafterpreapplication (10seconds)
and coapplication of A-867744 (1 mM; right). (C) Representative traces
illustrating responses to TQS (30 mM; left) together with TQS responses
from the same oocyte after preapplication (10 seconds) and coapplication of
A-867744 (1 mM; right). (D) Representative traces illustrating responses to
TBS-516 (10 mM; left) together with TBS-516 responses from the same
oocyte after preapplication (10 seconds) and coapplication of A-867744
(1 mM; right).
Fig. 4. Allosteric modulation of a7L247T by A-867744, TBS-516, and TQS.
Mutated a7L247T nAChRs were expressed in Xenopus oocytes and exam-
ined by two-electrode voltage-clamp recording. (A) Concentration-response
data illustrating agonist activation by TBS-516 and TQS but the absence of
agonist activity with A-867744. Data are the mean 6 S.E.M. of three
independent experiments, each from different oocytes. Data are normal-
ized to the maximum acetylcholine response. (B) Representative traces
illustrating responses to acetylcholine (10 mM; left) together with acetyl-
choline responses from the same oocyte after preapplication (10 seconds)
and coapplication of A-867744 (1 mM; right). (C) Representative traces
illustrating responses to TQS (10 mM; left) together with TQS responses
from the same oocyte after preapplication (10 seconds) and coapplication of
A-867744 (1 mM; right). (D) Representative traces illustrating responses to
TBS-516 (10 mM; left) together with TBS-516 responses from the same
oocyte after preapplication (10 seconds) and coapplication of A-867744
(1 mM; right).
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Allosteric Modulation of a7S222M. A mutation (S222M)
located in the TM1 domain of a7 (a7S222M) has been reported
to reduce but not abolish the potentiation of acetylcholine
responses by the type II PAM PNU-120596 (Young et al.,
2008). In agreement with these findings, both TBS-516 and
TQS retained PAM activity on a7S222M by potentiating peak
responses and reducing desensitization (Fig. 6, A and B). In
contrast, whereas A-867744 also caused a reduction in de-
sensitization, it caused a reduction of agonist-evoked responses
on a7S222M (Fig. 6C). Studies with a range of A-867744
concentrations indicate an incomplete block, reducing responses
to acetylcholine to 33%6 3.0% (n5 7) with IC50 value of 3.16
1.4 mM (n 5 4) (Fig. 6, D and E). Acetylcholine concentration-
response curves obtained in the absence and presence of
A-867744 (1.5 mM) show a nonsurmountable block by
A-867744 (Fig. 6D), which is characteristic of noncompetitive
antagonism. The acetylcholine EC50 values were not signifi-
cantly different for the curves in the absence and presence of
A-867744 (80.6 6 16.2 and 37.8 6 27.2 mM, respectively; P 5
0.06; n5 3). However, maximum current (Imax) in the presence
of A-867744 was significantly reduced (26.4%6 6.6% of control;
P , 0.001, n 5 3).
Allosteric Modulation of a7W54A. In addition to trans-
membrane mutations influencing allosteric modulation of a7
nAChRs, dramatic effects have also been reported for a
mutation (W54A) located in the extracellular domain, near
the orthosteric binding site. For example, it has been reported
that type II PAMs are converted into agonists in a7W54A
(Papke et al., 2014). In agreement with these previous
findings, both TBS-516 and TQS exhibited agonist effects on
a7W54A with EC50 values of 4.1 6 0.6 and 1.5 6 0.5 mM,
respectively (Fig. 7A). In contrast, A-867744 had no detectable
agonist activity on a7W54A but retained its PAM activity
(Fig. 7B). The maximum fold potentiation of the response to
acetylcholine (100 mM) by A-867744 was 15.1 6 1.8-fold
(n 5 12), which is not significantly different from that
observed with wild-type a7 nAChRs (17.1 6 2.7-fold; n 5 7;
P 5 0.54). In addition, it was found that A-867744 (1 mM)
blocked agonist responses elicited by TBS-516 and TQS on
a7W54A (Fig. 7, C and D).
Refined a7 nAChR Comparative Models. To examine
by computational approaches the possible interaction of PAMs
with the a7 nAChR, comparative structural models were
constructed based on the cryo-EM structures of the Torpedo
nAChR in its closed and open states (Unwin, 2005; Unwin and
Fujiyoshi, 2012). A previously reported error in the register of
amino acids within the transmembrane domain of the 4.0 Å
resolution Torpedo nAChR structure has been examined.
Specifically, it appears that the register of amino acids in
TM2 andTM3 is out by four amino acids due to the assignment
of an extra turn of the a-helix in TM1 (Corringer et al., 2010;
Hibbs and Gouaux, 2011; Mnatsakanyan and Jansen, 2013).
The discrepancy was identified as beginning after the residue
Y234 in TM1 (Fig. 8, A and B). In the present study, this error
has been corrected via a hierarchical refinement protocol
using additional cryo-EM density maps of Torpedo nAChR in
closed and open conformations (Materials and Methods)
(Supplemental Fig. 1; Supplemental Table 2). After correction,
the a-helical region of TM1 terminates at F233, a position
analogous to that of the 5-HT3 receptor (Fig. 8B). The
corrected closed and open structures of the Torpedo nAChR
ag subunit were used as a template on which to model the
human a7 nAChR on the basis of their close sequence identity
of 46% overall in the transmembrane region and 54% for
the TM1-TM3 region (Supplemental Fig. 2; Supplemental
Table 2). Models of the a7 subunit were generated that
contained the extracellular and transmembrane domains
but omitted the more divergent intracellular TM3-TM4 loop.
Pentameric a7 nAChR models were then constructed by apply-
ing 5-fold symmetry (Materials and Methods) (Supplemental
Fig. 3). Having corrected the assignment of amino acid positions
within the transmembrane domain of the Torpedo nAChR
models, the a7 comparative models had the same register of
Fig. 5. Allosteric modulation of a7M253L by A-867744, TBS-516, and TQS.
Mutated a7M253L nAChRs were expressed in Xenopus oocytes and
examined by two-electrode voltage-clamp recording. (A) Representative
traces illustrating responses to acetylcholine (100 mM; left), acetylcholine
responses after preapplication (10 seconds) and coapplication of TQS
(10 mM; middle), and response to acetylcholine after washing (right). (B)
Representative traces illustrating responses to acetylcholine (100 mM;
left), acetylcholine responses after preapplication (10 seconds) and coap-
plication of TBS-516 (10 mM; middle), and response to acetylcholine after
washing (right). (C) Representative traces illustrating responses to
acetylcholine (100 mM; left), and block of acetylcholine responses after
preapplication (10 seconds) and coapplication of A-867744 (1 mM; middle).
The acetylcholine response did not recover, even after a prolonged
(10minutes) wash (right). (D) Representative traces illustrating responses
to acetylcholine (100mM; left) and after preapplication of TQS (10 seconds),
preapplication of A-867744 and TQS (5 seconds), and then coapplication of
A-867744 (1 mM) and TQS (10 mM) (middle). TQS was preapplied for
10 seconds and A-867744 for 5 seconds. The acetylcholine response did not
recover, even after a prolonged (10 minutes) wash (right). (E) Concentra-
tion-response data illustrating inhibition by A-867744 of responses to
acetylcholine (100 mM). Data are the mean 6 S.E.M. of four independent
experiments, each from different oocytes.
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amino acids as found in an NMR structure of the a7 trans-
membrane domain (Mowrey et al., 2013). In addition, compar-
ison between the open and closed conformations revealed a
concerted movement of all four helices in the TM domain.
Analysis of the channel lumen of the two a7 structural models
with PoreWalker (European Bioinformatics Institute, Wellcome
Genome Campus, UK) (Pellegrini-Calace et al., 2009) revealed a
dilation between the closed and open a7 comparative models
(Supplemental Fig. 3).
Molecular Docking. To identify potential binding sites
for PAMs in the a7 nAChR closed and open comparative
models, a consensus small-molecule docking protocol was
developed (see Materials and Methods) (Supplemental Fig.
4). Docking was performed with a series of 37 compounds that
have close chemical similarity to A-867744 (eight compounds),
TBS-516 (four compounds), or TQS (25 compounds), all of
which are known to display type II PAM activity on a7
nAChRs (for details of the selected compounds, see Supple-
mental Table 1). After the docking simulation, the top five
ranked solutions from each chemical class were clustered
against each other by hierarchical RMSD clustering. The
latter step was performed to identify binding modes predicted
consistently across multiple compounds with a similar chem-
ical structure (Materials and Methods). For each of the three
classes of arylsulfonamide type II PAMs, the most highly
populated clusters were assumed to represent the most
probable location of the binding site. The docking protocol
resulted in the largest binding mode clusters located in an
intersubunit cavity (Fig. 9). For the group of compounds
chemically related to TBS-516 and TQS, a high degree of
similarity was observed between the binding mode clusters
identified in the closed and open models (Fig. 9). The
arylsulfonamide groups were predicted to interact with the
lower TM2-TM3 interface, forming hydrogen bonds with S284
and/or T288 (Fig. 9). In contrast, the predicted consensus
bindingmodes for the series of compounds related to A-867744
were in significantly different orientations to the group of
PAMs with chemical similarity to TBS-516 and TQS (Fig. 9).
For example, in both conformations the predicted consensus
bindingmode did not show any hydrogen bondingwith S284 or
T288. Furthermore, the arylsulfonamide group, a common
fragment in all three classes of compound, was predicted to
form very different interactions for the A-867744 compound
set than for the TBS-516 or TQS compound sets (Fig. 9).
Interface sizes of the docked protein-ligand complexes were
determined using the Protein Interfaces, Surfaces, and As-
semblies service PISA at the European Bioinformatics In-
stitute (Krissinel and Henrick, 2007) and were found to be
comparable to those in the template structures (Supplemental
Table 3).
Predicted Binding of TBS-516 and TQS. Predicted
binding mode clusters for both TBS-516 and TQS and their
related compounds occupy strikingly similar locations in both
closed and open receptor models (Fig. 9; Supplemental Fig. 7).
Notably, in the closed conformation, potential hydrogen bonds
were observed for the arylsulfonamides of both compounds
with the residues S284 and T288 at the cytoplasmic end of
TM3 (Fig. 9). These residues are involved in the TM2-TM3
Fig. 6. Allostericmodulation of a7S222M by A-867744, TBS-516, and TQS.Mutated a7S222M nAChRs were expressed inXenopus oocytes and examined by
two-electrode voltage-clamp recording. (A) Representative traces illustrating responses to acetylcholine (100 mM; left), acetylcholine responses after
preapplication (10 seconds) and coapplication of TQS (10 mM; middle), and response to acetylcholine after washing (right). (B) Representative traces
illustrating responses to acetylcholine (100 mM; left), acetylcholine responses after preapplication (10 seconds) and coapplication of TBS-516 (10 mM;
middle), and response to acetylcholine after washing (right). (C) Representative traces illustrating responses to acetylcholine (100 mM; left), block of
acetylcholine responses after preapplication (10 seconds) and coapplication of A-867744 (1 mM; middle), and response to acetylcholine after washing
(right). (D) Agonist concentration-response curve for acetylcholine in the absence and presence of A-867744 (1.5 mM; preapplied for 10 seconds and then
coapplied with acetylcholine). Data are the mean 6 S.E.M. of at least three independent experiments and are normalized to the maximum response
obtained with ACh in the absence of A-867744. (E) When A-867744 was preapplied and coapplied with acetylcholine, positive modulatory effects
(a reduction in agonist-evoked desensitization) was associated with a reduction in peak agonist responses.
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interface, possibly forming part of the desensitization gate of
pLGICs (Gielen et al., 2015). Consequently, such interactions
may help to explain changes in the rate of desensitization that
are observed with these type II PAMs. The naphthyl ring of
TQS sits in a hydrophobic pocket formed by the side chains of
the amino acids L247, S248, and F252 of the (2) subunit, and
L246, L247, T250, andM253 of the (1) subunit, and is situated
∼6.5 Å from M253 and ∼5.0 Å from L247, both of which are
amino acids that have been mutated in this study. In the
TBS-516 compounds, a similar pocket is occupied by either
the benzyl ring (4.0 Å to M253 and 3.5 Å to L247) or the
bromophenyl ring (7.2 Å to M253 and 3.5 Å to L247) in
the closed and open conformations, respectively. The close
proximity of TQS and TBS-516 toM253 and L247may explain
their observed pharmacological effects on the respective
mutants.
In the open conformation, the TQS naphthyl ring remains in
the same hydrophobic pocket (Fig. 9). Unlike TBS-516, the
arylsulfonamide of TQS is farther away from S284 and T288,
no longer forming hydrogen bonds with these residues (Fig. 9)
but is within ∼3.5 Å of G242, another residue that has been
suggested to contribute to the desensitization gate of pLGICs
(Gielen et al., 2015). Nonetheless, the cluster of bindingmodes
for TQS predicted in the open conformation covers a broader
area than that predicted in the closed conformation (Fig. 9),
and many of the other members of the cluster maintain
hydrogen bonding interactions with S284 and T288, as well
as forming hydrogen bonds to the protein backbone at G242.
For TBS-516, the bromophenyl ring sits in the same hydro-
phobic pocket as the naphthyl ring of TQS (Fig. 9), whereas the
third variable group (a benzyl group) protrudes onto a
different hydrophobic surface, formed by L246, T250, M253,
M278, and V281 (Fig. 9).
Predicted Binding of A-867744. The predicted binding
modes of A-867744 and related compounds are in a location
similar to those of TBS-516 and TQS but have subtle yet
important differences (Fig. 9). Most obviously, whereas the
arylsulfonamide group of the TBS-516 and TQS clusters is
orientated downward in both the open and closed receptor
conformation, it is orientated upward for the A-867744 cluster
(Fig. 9; Supplemental Fig. 7) In the closed conformation, the
arylsulfonamide group of A-867744 forms a hydrogen bond
with S248 of the (2) subunit (an amino acid predicted to
interact with both TBS-516 and TQS). However, the orienta-
tion of themolecule is different from that of TBS-516 and TQS,
situated between the TM2 and TM3 helices, with a protrusion
into the intrasubunit cavity, ∼7.0 Å from S222 (another amino
acid mutated in this study) (Fig. 9). TBS-516 and TQS are
predicted to lie much farther from this residue in the closed
conformation (∼14.0 Å), which may explain how the S222M
mutation has a dramatic effect on A-867744, but not on TBS-
516 or TQS (Fig. 9).
Interestingly, in the open conformation, the predicted
binding mode for A-867744 is very different from its closed
conformation counterpart (closer to the extracellular domain)
(Fig. 9). The arylsulfonamide appears to form hydrogen bonds
with T277 and T250, which is markedly different from its
interactions in TQS or TBS-516 (Fig. 9); however, it is still
located in the TM2-TM3 interface, perhaps influencing the
possible desensitization gate. The phenyl ring of the arylsul-
fonamide is located on the same hydrophobic surface as
described for TBS-516 (Fig. 9). The chlorophenyl ring is also
predicted to be embedded in the same hydrophobic pocket as
that described for the naphthyl ring of TQS, close to L247 and
M253 (Fig. 9).
Discussion
The pharmacological properties of three type II PAMs
(A-867744, TBS-516, and TQS) have been examined on five
different mutants of the a7 nAChR (W54A, S222M, L247T,
M253L, and M260L). In all cases, the effects on the action of
A-867744 were different from those observed with two other
arylsulfonamide type II PAMs (Table 1). This is consistent
with previous studies that have suggested that A-867744 is an
a7 PAM with unusual properties (Malysz et al., 2009a).
Prior to the present study, one of the primary reasons for
concluding that A-867744 had atypical properties was that it
caused dissociation of [3H]-A-585539 (Malysz et al., 2009a), an
a7-selective agonist that is thought to bind at the orthosteric
site (Anderson et al., 2008). However, studies with subunit
chimeras suggest that A-867744 exerts its potentiating effects
Fig. 7. Allosteric modulation of a7W54A by A-867744, TBS-516, and TQS.
Mutated a7W54A nAChRs were expressed in Xenopus oocytes and exam-
ined by two-electrode voltage-clamp recording. (A) Concentration-response
data illustrating agonist activation by TBS-516 andTQS but the absence of
agonist activity with A-867744. Data are the mean 6 S.E.M. of three
independent experiments, each from different oocytes. Data are normal-
ized to the maximum acetylcholine response. (B) Representative traces
illustrating responses to acetylcholine (100 mM; left) together with
acetylcholine responses fromthesameoocyteafterpreapplication (10seconds)
and coapplication of A-867744 (1 mM; right). (C) Representative traces
illustrating responses to TQS (10 mM; left) together with TQS responses
from the same oocyte after preapplication (10 seconds) and coapplication of
A-867744 (1 mM; right). (D) Representative traces illustrating responses to
TBS-516 (10 mM; left) together with TBS-516 responses from the same
oocyte after preapplication (10 seconds) and coapplication of A-867744
(1 mM; right).
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by binding at a transmembrane site (Malysz et al., 2009a).
This is also consistent with evidence that A-867744 does not
displace binding of orthosteric antagonists such as [3H]-a-BTX
(the present study) or [3H]-MLA (Malysz et al., 2009a). One
possible explanation is that the binding of A-867744 to a
transmembrane binding site results in the stabilization of a
different open conformation to that of other type II PAMs.
Numerous a7 mutations have been reported to alter the
properties of orthosteric and allosteric ligands. Although some
mutations, such as M260L, have differing effects on type I and
type II PAMs (Chatzidaki et al., 2015), mutations generally
appear to have consistent effects on compounds that have
similar effects on wild-type a7 nAChRs, such as type II PAMs
(Chatzidaki et al., 2015). The identification of mutations that
have differing effects on A-867744 than those on other type II
PAMs, provides evidence that A-867744 has an atypical
mechanism of action. An explanation might be that
A-867744 binds at an allosteric site on a7 that is different
from the binding sites of other PAMs. This could be due to the
PAMs interacting in different ways at a common or over-
lapping site, or perhaps binding at unrelated sites. Binding to
a common site would be consistent with the observation that
A-867744 is able to block the effects of the other PAMs on these
mutants.
Recently, an X-ray structure of the a4b2 nAChR (PDB ID
5KXI) has been determined (Morales-Perez et al., 2016). In
Fig. 8. Refinement of the transmembrane domain of the Torpedo nAChR ag subunit. (A) Sequence alignment and structural superposition of the TM1-
TM2 loop region and TM2 helix of theTorpedo ag subunit (PDB ID 2BG9; chain A) with that of the 5-HT3 receptor (PDB ID 4PIR; chain A) andGLIC (PDB
ID 4HFI; chain A). As has been described previously (Supplemental Fig. 21 in Hibbs and Gouaux, 2011), amino acids from the TM1-TM2 loop of the
Torpedo nAChR (e.g., Y234) superposewell with homologous amino acids from other pLGIC structures (C239 of 5-HT3R andW217 of GLIC; indicated by a
straight line in the sequence alignment). In contrast, amino acids within the nAChR TM2 domain are out of register by ∼1 turn of the a-helix when
comparedwith other pLGIC structures (e.g., compare E262 of the nAChR structure with D267 of 5-HT3R and T241 of GLIC; indicated by an angled line in
the sequence alignment). (B) Alignment of amino acid sequence of the b10 strand and TM1 helix ofTorpedo nAChR a subunit with that of related pLGICs
(top panel). Also shown is the secondary structure before refinement (middle panel) and after refinement (bottom panel) of the Torpedo nAChR structure.
Structural information is derived from the following PDB files: nAChR (2BG9; chain A), 5-HT3 receptor (4PIR; chain A), GABAA receptor (4COF; chain A),
glycine receptor (3JAD; chain A), and GLIC (4HFI; chain A). Arrows denote b-strands, spirals denote a-helices, conserved residues are highlighted with
white text on a red background, and residues with similar properties are highlighted with red text on a white background.
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addition, the structure of the transmembrane domain of the
a7 nAChR has been studied by NMR but corresponds to an
unassembled subunit monomer and contains deletions and
amino acid substitutions (Mowrey et al., 2013). Both of these
structures were derived from detergent-solubilized proteins,
and, because of concerns that this may influence transmem-
brane structure, they were not selected as a starting point for
the docking studies. Additionally, when an a7 model built on
an a4 subunit of 5KXI was subjected to our docking protocol,
no consensus solutions were identified. This provides support
for the assumption that crystal structures may be less
appropriate starting points for docking to pLGIC transmem-
brane domains due to the absence of membrane lipids causing
tighter packing of the transmembrane domain, as reflected by
the increased interface size between subunits of a4b2 and
Torpedo nAChR models (Supplemental Table 3).
Our main rationale for using the Torpedo nAChR to
generate a7 models is that it is the only pLGIC structure to
have been determined in a lipid membrane environment. This
may be important in preserving the native structure of the
transmembrane domain. Thus, our approach was to use the
Torpedo nAChR structure to generate an a7 model but also to
correct an error that had been identified in the assignment of
amino acids within the transmembrane domain of theTorpedo
nAChR model (Corringer et al., 2010; Hibbs and Gouaux,
2011; Mnatsakanyan and Jansen, 2013). A further benefit of
using the Torpedo nAChR is that structures were determined
in both the closed and open conformations, allowing us to
generate two analogous conformations of a7.
Evaluation of our corrected structures suggested that they
represented a higher-quality model of the transmembrane
region (Supplemental Fig. 5). The gating motion between
closed and open conformations of our comparative models
reveals a concerted rotation of the four TMhelix bundle of each
domain, which is similar to gatingmechanisms that have been
proposed from studies with other pLGICs (Calimet et al.,
2013; Du et al., 2015).
Ligands binding to transmembrane regions are less likely to
form high-affinity interactions due to the lack of polar
residues, and this can limit the success of docking studies.
Therefore, we used a consensus docking approach that
examined a group of compounds with chemical and pharma-
cological similarity to the three compounds of primary interest
(A-867744, TBS-516, and TQS) in two independent docking
programs. Our justification being that previous studies have
suggested that a consensus docking approach can improve the
reliability of docking predictions (Houston and Walkinshaw,
2013).
All three groups of type II PAMs were predicted to bind in
the intersubunit transmembrane region (Fig. 9). This is
different from what was previously predicted for some
allosteric modulators of a7 (e.g., LY-2087107, NS-1738, and
PNU-120596) where an intrasubunit site was proposed
(Young et al., 2008; Collins et al., 2011; Gill et al., 2011). We
attribute this difference to the previous studies being con-
ducted with a7 comparative models that were based upon
an uncorrected model of the Torpedo nAChR. Indeed, we
have also now performed consensus docking studies with
LY-2087107, NS-1738, and PNU-120596 in our new a7
comparative model and found that these PAMs are also
predicted to bind in an intersubunit site (Supplemental Fig. 6).
Our prediction of an intersubunit binding site for a7
allosteric modulators is consistent with the fact that another
allosteric modulator (ivermectin) is known to bind at the
Fig. 9. Docking of A-867744, TBS-516, and TQS and into a7 structural models. After docking studies with the closed and open models (top and bottom
panels, respectively), representatives of bindingmode clusters are illustrated forA-867744 (AandD; purple). TBS-516 (BandE; orange), andTQS (C andF;
cyan). Amino acids that are discussed in the text are shown in stick representation. Predicted hydrogen bonds are shownwith dashed lines. In each case, the
principal subunit is shown in khaki (on the left in each panel) and the complimentary subunit is shown in olive (on the right in each panel).
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intersubunit cavity, based on cocrystallization with two
different pLGICs (Althoff et al., 2014; Du et al., 2015). In
addition, an intersubunit transmembrane binding site has
been identified on the basis of affinity-labeling studies with
purified Torpedo nAChRs and photoreactive allosteric modu-
lators (Nirthanan et al., 2008; Hamouda et al., 2011).
Our experimental data are consistent with A-867744, TBS-
516, and TQS binding in a mutually exclusive manner to an
overlapping binding site. For example, preapplication of
A-867744 to a7L247T prevents allosteric activation by TBS-
516 and TQS (Fig. 4). Similarly, preapplication of TQS to a7
M253L prevents antagonism by A-867744 (Fig. 5). However,
our finding that A-867744 exerts pharmacological effects
distinct from those of TBS-516 and TQS on mutated a7
nAChRs suggests that A-867744 interacts by a different
mechanism. It is interesting that a mutation in the extracel-
lular domain (W54A) influences the activity of these PAMs
(presumably, a consequence of long-range effects on receptor
structure), yet it has a different effect on A-867744 than on
TBS-516 and TQS (Fig. 7; Table 1) This is consistent with
previous evidence indicating, unexpectedly, that A-867744
can cause the dissociation of [3H]-A-585539 from the orthos-
teric site (Malysz et al., 2009a).
Our docking studies appear to be consistent with the
experimental findings. Docking studies suggest that
A-867744 binds in an orientation that is distinct from that of
both TBS-516 and TQS (most apparent in the closed model)
(Fig. 9; Supplemental Fig. 7). This provides a basis for
understanding how both proximal and distant mutations
affect the function of A-867744 differently from how they
affect TBS-516 and TQS. However, despite these differences,
all three compounds are predicted to bind in a broadly similar
transmembrane location that is in proximity to residues that
have been implicated in the desensitization gate of pLGICs
(Gielen et al., 2015).
It is notable that some of the mutations examined (S222M,
L247T, and M253L) convert A-867744 into an antagonist but
do not have this effect with either TBS-516 or TQS (Table 1). In
the closed conformation, A-867744 is predicted to bind with a
moiety protruding between the TM2 and TM3 helices of the
principal subunit, while forming a hydrogen bond with the
complimentary subunit (Figs. 9 and 10; Supplemental Fig. 7).
This may allow A-867744 to act as a physical barrier to the
normal movement of transmembrane helices. It is possible
that some transmembranemutationsmay increase the energy
barrier for transition between closed and open states when
A-867744 is bound, causing the observed inhibition of agonist-
evoked responses. Alternatively, A-867744 may be acting as
an open-channel blocker on receptors containing some trans-
membrane mutations. However, evidence that other PAMs
can block the inhibitory effect of A-867744 (Fig. 5C) provides
support for the conclusion that positive and negative modula-
tory effects can occur through a broadly similar mutually
exclusive binding site.
In summary, evidence has been obtained from a7 nAChRs
containing five different point mutations indicating that
A-867744 exerts its allosteric effects via a mechanism that is
distinct from other type II PAMs. Docking simulations in the
transmembrane regions of new structural models of the
human a7 nAChRs suggest how PAMs such as A-867744,
TBS-516, and TQS interact with an intersubunit transmem-
brane site and provide an explanation of the pharmacological
Fig. 10. Intersubunit transmembrane binding site for PAMs on the a7 nAChR. (A) Representation of the transmembrane domain viewed from above,
looking down the axis of the channel pore. Black ellipses indicate the location of the intersubunit allosteric binding site identified in this study.
(B) Predicted binding modes in the closed and open receptor models of A-867744 (purple), TBS-516 (orange), and TQS (cyan), shown in relation to
transmembrane helices (gray rods) from the principal (+) and the complementary (2) subunit interface. The locations of predicted hydrogen bonds are
shownwith chain links to denote anchoring of the ligands within the binding site. The locations of amino acidsM253, L247, and S222 are shown as yellow,
blue, and green circles, respectively. An arrow at the top of TM2 from the complementary subunit denotes the motion required for the change in
conformation from the open to the closed channel.
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diversity among this group of chemically similar allosteric
modulators.
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